Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9-14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial.

Saved in:
Bibliographic Details
Title: Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9-14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial.
Authors: Agbenyega T; Malaria Research Center, Agogo Presbyterian Hospital/Kwame Nkrumah University of Science and Technology, Agogo, Ghana., Schuind AE; PATH, Center for Vaccine Innovation and Access, Seattle, WA, USA. Electronic address: aschuind@path.org., Adjei S; Malaria Research Center, Agogo Presbyterian Hospital/Kwame Nkrumah University of Science and Technology, Agogo, Ghana., Antony K; PATH, Center for Vaccine Innovation and Access, Seattle, WA, USA., Aponte JJ; PATH, Center for Vaccine Innovation and Access, Seattle, WA, USA., Buabeng PBY; Malaria Research Center, Agogo Presbyterian Hospital/Kwame Nkrumah University of Science and Technology, Agogo, Ghana., Clemens JD; International Vaccine Institute, Seoul, South Korea; Center for Vaccine Innovation, Seoul, South Korea; UCLA Fielding School of Public Health, Los Angeles, CA, USA., Hossain L; Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh., Kemp TJ; HPV Serology Laboratory, Vaccine, Immunity, and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Mercer LD; PATH, Center for Vaccine Innovation and Access, Seattle, WA, USA., Pinto LA; HPV Serology Laboratory, Vaccine, Immunity, and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Qadri F; Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh., Sukraw K; PATH, Center for Vaccine Innovation and Access, Seattle, WA, USA., Bhat N; PATH, Center for Vaccine Innovation and Access, Seattle, WA, USA., Zaman K; Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.
Source: The Lancet. Infectious diseases [Lancet Infect Dis] 2025 Aug; Vol. 25 (8), pp. 861-872. Date of Electronic Publication: 2025 Mar 19.
Publication Type: Clinical Trial, Phase III; Equivalence Trial; Journal Article; Randomized Controlled Trial
Journal Info: Publisher: Elsevier Science Country of Publication: United States NLM ID: 101130150 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4457 (Electronic) Linking ISSN: 14733099 NLM ISO Abbreviation: Lancet Infect Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-4457
DOI:10.1016/S1473-3099(25)00031-3